Css (mg/l) Mean±SD | P value (ANOVA) | CL (ml/kg.min) Mean±SD | P value (ANOVA) | AUC (μg.h/ml) Mean±SD | P value (ANOVA) | |
Meropenem (n=Css determinations) | ||||||
(A) Dose adjustment not required and no CRRT (n=26) | 20.7±10.3 | <0.0001 | 3.2±1.6 | <0.0001* | 74.6±37.9 | <0.0001 |
(B) Dose adjustment required and no CRRT (n=6) | 65.5±25.4 | 0.8±0.3 | 234.3±91.4 | |||
(C) With CRRT (n=9) | 39.8±16.4 | 1.18±0.3 | 139.8±59.1 | |||
All cases (n=41) | 30.8±21.4 | 2.43±1.7 | 110.8±76.9 | |||
Piperacillin | ||||||
(A) Dose adjustment not required and no CRRT (n=63) | 72.5±46.8 | <0.0001† | 3.8±2.6 | <0.0001† | 261.0±168.4 | <0.0001† |
(B) Dose adjustment required and no CRRT (n=24) | 138.6±44.5 | 1.1±0.5 | 499.1±160.1 | |||
(C) With CRRT (n=40) | 138.4±57.9 | 1.2±0.6 | 498.2±208.6 | |||
All cases (n=127) | 108.8±59.0 | 2,5±2.0 | 380.0±212.5 |
*Differences not statistically significant between groups B and C.
†Differences not statistically significant between groups B and C.
AUC, area under the curve; CL, clearance; CRRT, continuous renal replacement therapy; Css, serum concentration at steady state.